Acadia Pharmaceuticals 3Q 2026: Revenue $342.29M, EPS $0.31 — 10-Q Summary
Acadia Pharmaceuticals reported Q3 2026 revenue of $342.29M, up 22.8% YoY, driven by sales growth in NUPLAZID and DAYBUE products. Net income fell 25.4% to $53.52M due to higher SG&A expenses, partly offset by lower R&D spending. NUPLAZID sales rose to $202.2M, while DAYBUE sales increased to $140.1M.
How this was made
The 30-second read
Why it matters
The earnings miss may trigger short‑term sell pressure, but pipeline progress could support longer‑term recovery.
Market read
First disclosure of Q3 results; traders may adjust positions based on earnings miss.
What to watch
Phase‑2 trial miss may be offset by upcoming Phase‑3 studies, offering future upside.
Background
Acadia Pharmaceuticals filed its Q3 2026 10‑Q, reporting revenue growth and EPS decline.
Ticker impact
Q3 2026 10‑Q shows revenue up 22.8% YoY but EPS down 26.2%, indicating mixed earnings impact.
likely pressure as investors price in lower earnings per share.
Revenue growth is modest while EPS fell sharply, suggesting margin compression.
Market effects
Biotech sector may see slight downside pressure as earnings miss highlights execution risk.
U.S. biotech stocks could face modest pullback in after‑hours trading.
Limited to investors tracking U.S. pharma earnings.
Counterpoint
Revenue growth could signal longer‑term upside if cost discipline improves.
Key entities
- CompanyAcadia Pharmaceuticals
Biotech firm developing treatments for CNS disorders.
